ARS Pharmaceuticals, Inc. (SPRY)
4.29
+0.06
(+1.42%)
USD |
NASDAQ |
Oct 20, 16:00
4.305
+0.02
(+0.35%)
After-Hours: 20:00
ARS Pharmaceuticals Research and Development Expense (TTM) : 15.23M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 15.23M |
| March 31, 2026 | 14.56M |
| December 31, 2025 | 13.18M |
| September 30, 2025 | 12.76M |
| June 30, 2025 | 14.44M |
| March 31, 2025 | 17.30M |
| December 31, 2024 | 19.58M |
| September 30, 2024 | 19.96M |
| June 30, 2024 | 18.54M |
| March 31, 2024 | 18.95M |
| December 31, 2023 | 20.27M |
| September 30, 2023 | 21.56M |
| Date | Value |
|---|---|
| June 30, 2023 | 22.45M |
| March 31, 2023 | 19.50M |
| December 31, 2022 | 18.37M |
| September 30, 2022 | 29.35M |
| June 30, 2022 | 40.90M |
| March 31, 2022 | 54.09M |
| December 31, 2021 | 60.72M |
| September 30, 2021 | 53.68M |
| June 30, 2021 | 44.44M |
| March 31, 2021 | 31.89M |
| December 31, 2020 | 24.11M |
| September 30, 2020 | 21.74M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Capricor Therapeutics, Inc. | 98.66M |
| Sionna Therapeutics, Inc. | 72.04M |
| Nektar Therapeutics | 131.74M |
| Ardelyx, Inc. | 83.87M |
| Kyntra Bio, Inc. | 22.86M |